Food for Thought: How Bad is Big Pharma? An Analysis of Public Perception in the U.S.

Despite growing complaints about the negative reputation of the pharmaceutical industry, little fundamental research data has been available on the topic so far.

A detailed analysis by George P.  Sillup and Stephen J. Porth published in the International Journal of Pharmaceutical and Healthcare Marketing supports the evidence. Following an audit of the top five U.S. newspapers over two years (2004-2005), Sillup and Porth concluded that the overall coverage of the pharmaceutical industry was primarily negative (69.5% and 60.1% in 2004 and 2005, respectively) and that “pharmaceutical companies need to take action to address the negative impression about them.”

In our view, the findings underline the importance of a sustainable, long-term communication strategy targeting all relevant stakeholders, including patients and the general public.

Further details and the full article (pdf) can be found at the Emerald Insight website:

Source: George P.  Sillup and Stephen J. Porth in the International Journal of Pharmaceutical and Healthcare Marketing, Vol. 2 No. 3, 2008, pp. 163-180

Food for Thought: An Artificial Tree to Remove CO2 from the Atmosphere

Reducing carbon dioxide emission is an enormous task, removing it from the atmosphere at low cost anywhere in the world maybe much more efficient and easier to accomplish (and faster!).

Imagine a bottle brush where all the bristles are artificial leaves – that‘s exactly the device Klaus S. Lackner, Director of the Lenfest Center for Sustainable Energy at Columbia University has developed.

The idea goes back to his daughter Claire who at school in an eighth grade science fair project demonstrated that carbon dioxide can be captured from the air in an acid/base reaction, simply by using a fish tank pump and sodium hydroxide. Actually, the simple device removed half of the carbon dioxide that ran through the apparatus.

The success struck her father who founded Global Research Technologies LLC (GRT) and within a year developed the bottle brush resembling device.

GRT‘s ACCESS™ air-capture system simply collects CO2 on a proprietary sorbent and later releases it again, while cleaning and pressurizing the gas to meet the specifications of CO2 storage or end-use. The GRT air-capture system is about one thousand times more efficient than a tree of equal size, in large part because the GRT collector does not need to capture sunlight. Its “leaves” can be packed tightly without concern over shading, and the system will function 24 hours a day. The CO2 harvested is removed from the sorbent and stored or used for a range of already existing commercial applications.

The CO2 balance is quite favorable, Lackner claims, with production and processing using only 1/5th of the CO2 amount that is being absorbed. He estimates the costs at the beginning to be $300 per ton of CO2 which might be reduced to $30 per ton with mass production.

Company News: SuppreMol Appoints Dr. Robert Phelps as Head of Business Development & Licensing

SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that Dr. Robert Phelps has joined the Company as Head of Business Development & Licensing.

See the full release at SupperMol´s website.

Company News: Indivumed to Study the Integrity of Biospecimen Sampling Procedures for the U.S. National Cancer Institute

Analysis of biopsy sampling procedures a prerequisite for the development of future individualized cancer therapies

Hamburg-based Indivumed GmbH has been awarded a subcontract by SAIC-Frederick, Inc., under its prime contract with the U.S. National Cancer Institute (NCI) to assess the impact of sampling procedures on the integrity of cancer biospecimens and key data derived from them.

The NCI’s Office of Biorepositories and Biospecimen Research (OBBR) is sponsoring the study to better understand how the integrity of voluntarily donated medical biospecimens—such as blood and biopsy tissue—might be compromised by the way in which they are collected and handled. Surgical and tissue sampling procedures can affect cellular processes in these biospecimens, influencing the results of research on cancer targets and mechanisms. Despite widespread use of cancer biospecimens for research, there are currently no systematic data available assessing the influence of sampling procedures on the molecular processes and compositions of the collected tissue.

Indivumed and its clinical network partners have pioneered standards to enable full control of all steps in tissue collection and clinical data collection, and are thus prepared to study the impact of intra- and post-surgical tissue processing on molecular data. For further details, please see the full announcement.

1 183 184 185